What is HC Wainwright's Forecast for OLMA FY2029 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($2.41) for the year. HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share.

Separately, Oppenheimer reissued an "outperform" rating and set a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Stock Up 2.1 %

Shares of OLMA traded up $0.09 during mid-day trading on Thursday, reaching $4.32. The company's stock had a trading volume of 3,604,605 shares, compared to its average volume of 816,929. The company has a market cap of $247.53 million, a price-to-earnings ratio of -1.97 and a beta of 2.11. The business has a fifty day moving average of $5.08 and a 200 day moving average of $8.25. Olema Pharmaceuticals has a 1 year low of $3.94 and a 1 year high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Remove Ads

Insider Buying and Selling

In related news, major shareholder Bain Capital Life Sciences Inv bought 300,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, January 8th. The stock was purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the acquisition, the insider now owns 7,800,000 shares in the company, valued at $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its holdings in shares of Olema Pharmaceuticals by 52.1% during the 4th quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock worth $8,839,000 after buying an additional 522,799 shares during the period. Polar Asset Management Partners Inc. bought a new stake in Olema Pharmaceuticals during the fourth quarter valued at about $119,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Olema Pharmaceuticals by 23.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,979 shares of the company's stock valued at $548,000 after acquiring an additional 18,005 shares during the period. Squarepoint Ops LLC grew its position in shares of Olema Pharmaceuticals by 205.8% in the fourth quarter. Squarepoint Ops LLC now owns 48,829 shares of the company's stock valued at $285,000 after purchasing an additional 32,860 shares during the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Olema Pharmaceuticals by 30.2% in the fourth quarter. ProShare Advisors LLC now owns 14,226 shares of the company's stock worth $83,000 after purchasing an additional 3,298 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.